Cervical cancer is a malignancy of the cervix, second most common cancer of women. It may present with vaginal bleeding but symptoms may be absent until the cancer is in advanced stages, which has made cervical cancer the focus of intense screening efforts utilizing the Pap smear. Most scientific studies point to human papillomavirus (HPV) infection as a necessary pre-requisite for development of cervical cancer.
NEJM publishes new data on GARDASIL, Merck's Cervical Cancer Vaccine
Cervical Cancer :: NEJM publishes new data on GARDASIL, Merck's Cervical Cancer Vaccine
The New England Journal of Medicine is publishing results from two Phase III studies of Merck's cervical cancer vaccine, GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine].These significant results, observed in 15- to 26-year-old women who were not infected with the relevant HPV types when they began the study, were sustained through an average of three years of participation in the trials, including an additional year of follow up since data were presented to the U.S. Food and Drug Administration (FDA) for approval of GARDASIL.
"In these two studies, GARDASIL demonstrated significant protection against serious HPV-related diseases, including high-grade cervical pre-cancers, in women not previously exposed to the relevant HPV types targeted by the vaccine," said Kevin Ault, M.D., associate professor, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta. "Widespread immunization of 11- to 26-year-old girls and women with GARDASIL, along with continued screening, will help decrease the burden of cervical cancer and other HPV-related diseases."
It is estimated that in 2007, cervical cancer will strike more than 11,000 women in the U.S. and nearly 500,000 women around the world. GARDASIL helps protect against the four HPV types - 6, 11, 16 and 18 - that cause the most disease, including 70 percent of cervical cancer cases and 90 percent of cases of genital warts. All four types cause a large number of "abnormal" Pap test results and low-grade cervical lesions.
"My fellow investigators around the world are proud of these data and their contribution to our understanding of the impact of GARDASIL on risk for development of cervical, vulvar, and vaginal diseases caused by HPV 6, 11, 16, and 18," said Eliav Barr, M.D., executive director of Biologics Clinical Research and head of the HPV Vaccine Program, Merck Research Laboratories. "In women not infected with the four HPV types targeted by GARDASIL, GARDASIL reduced cervical disease caused by the relevant HPV types. And, across the larger study population, GARDASIL also reduced the overall burden of cervical, vulvar, and vaginal HPV diseases caused by HPV types targeted by the vaccine and by other HPV types."
GARDASIL was approved by the FDA on June 8, 2006, and is recommended for use by girls and women ages 11 to 26 by the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. GARDASIL is indicated for the prevention of HPV types 16- and 18- related cervical cancer, non-invasive cervical cancer [cervical intraepithelial neoplasia (CIN) grade 3 and adenocarcinoma in situ (AIS)], cervical pre-cancers [cervical intraepithelial neoplasia (CIN) grade 2], vulvar pre-cancers [vulvar intraepithelial neoplasia (VIN) 2/3)] and vaginal pre-cancers [vaginal intraepithelial neoplasia (VaIN) 2/3], and for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18. GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.
(Cervical Cancer :: NEJM publishes new data on GARDASIL, Merck's Cervical Cancer Vaccine published at SpiritIndia on Monday, May 14, 2007)
Cervical Cancer
Search more information on Cervical Cancer, Cervical Cancer booksRecently posted related articles on Cervical Cancer :
- Cervical Cancer :: Women still face cancer risk 25 years after treatment
- Cervical Cancer :: GSK seeks prequalification for Cervarix from WHO after obtaining marketing approval in Europe
- Cervical Cancer :: Greater investments needed to eliminate cervical cancer
- Cervical Cancer :: GSK submits Cervarix licence application to Japan's health authorities
- Cervical Cancer :: Cervarix, GSK's cervical cancer vaccine, approved in Europe
- HPV :: HPV facts presented during National Cervical Cancer Coalition conference
- HPV :: Cervical Cancer/HPV Conference tackles controversial vaccine issues
- Cervical Cancer :: New cervical cancer vaccine to be evaluated in Rochester
- HPV :: Milestones achieved in HPV Immunization for cervical cancer, Canada
- Cervical Cancer :: Visual inspection screening method is effective in reducing cervical cancer
Most related articles:
- Cervical Cancer :: NEJM publishes new data on GARDASIL, Merck's Cervical Cancer Vaccine- Cervical Cancer :: Merck's Gardasil vaccine - Australia immunisation program - 29.9
- Gardasil :: Merck's Gardasil for Vaginal and Vulvar Cancers - 25.7
- Cervical Cancer :: Bill would require cervical cancer vaccine for girls - 25.4
- Cervical Cancer :: Gardasil caervical cancer vaccine in Australia ! - 25.1
- Cervical Cancer :: UAE to introduce Gardasil cervical cancer vaccine - 24.7
- Gardasil :: Sanofi submitted new data to European Medicines Agency for HPV vaccine Gardasil - 24.4
- Gardasil :: Merck submits new cross-protection data for Gardasil to FDA - 24.3
- Cervical Cancer :: American Cancer Society releases guidelines on Merck's HPV cervical cancer vaccine Gardasil - 23.7
- Cervical Cancer :: Demand high for HPV shot - Gardasil cervical cancer vaccine - 23.7
Cervical Cancer - recent related articles/news stories:
- GSK's cervical cancer vaccine Cervarix got WHO prequalification- Early cervical cancer screening may harm women
- New gene silencing way to turn off cervical cancer genes
- Benefit to women not enough to sway men to get HPV vaccine
- Gardasil is eligible for UN immunization programs
»» Marijuana :: Medical Marijuana Bill Defeated in Senate, Supporters Vow to Try Again
«« HIV :: Highly sensitive and accurate Roche HIV-1 Test approved by FDA
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com